MA44037A1 - Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci - Google Patents
Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ciInfo
- Publication number
- MA44037A1 MA44037A1 MA44037A MA44037A MA44037A1 MA 44037 A1 MA44037 A1 MA 44037A1 MA 44037 A MA44037 A MA 44037A MA 44037 A MA44037 A MA 44037A MA 44037 A1 MA44037 A1 MA 44037A1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- treatment
- adrenergic receptor
- prevention
- associated therewith
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble médié par le récepteur adrénergique bêta 3, tel que l'insuffisance cardiaque, l'activité cardiaque dans l'insuffisance cardiaque, la mortalité, la récidive d'infarctus et/ou l'hospitalisation en relation avec l'insuffis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346293P | 2016-06-06 | 2016-06-06 | |
PCT/US2017/035867 WO2017214002A1 (fr) | 2016-06-06 | 2017-06-05 | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44037A1 true MA44037A1 (fr) | 2019-05-31 |
MA44037B1 MA44037B1 (fr) | 2020-03-31 |
Family
ID=59067920
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44037A MA44037B1 (fr) | 2016-06-06 | 2017-06-04 | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
MA045150A MA45150A (fr) | 2016-06-06 | 2017-06-05 | Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045150A MA45150A (fr) | 2016-06-06 | 2017-06-05 | Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier |
Country Status (29)
Country | Link |
---|---|
US (5) | US20190284200A1 (fr) |
EP (1) | EP3464292B8 (fr) |
JP (3) | JP6771246B2 (fr) |
KR (2) | KR20190026731A (fr) |
CN (1) | CN109563103B (fr) |
AR (1) | AR108772A1 (fr) |
AU (2) | AU2017278102B2 (fr) |
CA (1) | CA3026024A1 (fr) |
CL (1) | CL2018003451A1 (fr) |
CO (1) | CO2019000041A2 (fr) |
CR (1) | CR20180595A (fr) |
DK (1) | DK3464292T3 (fr) |
EA (1) | EA201892817A1 (fr) |
EC (1) | ECSP19001018A (fr) |
ES (1) | ES2929737T3 (fr) |
IL (2) | IL289378B (fr) |
MA (2) | MA44037B1 (fr) |
MX (2) | MX2018015124A (fr) |
MY (1) | MY195982A (fr) |
NI (1) | NI201800130A (fr) |
NZ (1) | NZ749202A (fr) |
PE (1) | PE20190445A1 (fr) |
PH (1) | PH12018502550A1 (fr) |
PT (1) | PT3464292T (fr) |
SG (1) | SG11201810788QA (fr) |
TN (1) | TN2018000391A1 (fr) |
TW (2) | TWI752963B (fr) |
UA (1) | UA125120C2 (fr) |
WO (1) | WO2017214002A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
HUE049979T2 (hu) | 2017-03-20 | 2020-11-30 | Forma Therapeutics Inc | Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként |
JP7357617B2 (ja) | 2017-12-06 | 2023-10-06 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 心不全およびそれに関連する障害の治療または予防に有用なβ-3アドレナリン受容体のモジュレーター |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
JP2023024954A (ja) * | 2021-08-09 | 2023-02-21 | アリーナ ファーマシューティカルズ, インコーポレイテッド | ベータ-3アドレナリン作動性受容体に関連する障害の処置または予防に有用なベータ-3アドレナリン作動性受容体のモジュレーター |
CA3230339A1 (fr) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulateurs du recepteur beta-3 adrenergique pour le traitement ou la prevention de la maladie kystique renale et du syndrome cardio-renal |
EP4413005A1 (fr) * | 2021-10-06 | 2024-08-14 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
WO2023154499A1 (fr) * | 2022-02-14 | 2023-08-17 | Biogen Ma Inc. | Inhibiteurs de protéines de liaison à l'emopamil (ebp) et leurs utilisations |
CN114539103B (zh) * | 2022-03-21 | 2023-04-07 | 佳木斯黑龙农药有限公司 | 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3028340C2 (de) * | 1980-07-25 | 1987-02-05 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
FR2751646B1 (fr) | 1996-07-23 | 1999-01-22 | Sanofi Sa | Phenoxypropanolamine a action antagoniste beta3-adrenergique |
WO1998027080A1 (fr) | 1996-12-19 | 1998-06-25 | Agrevo Uk Limited | Chromones utiles en tant que fongicides |
FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
AU2525801A (en) * | 1999-12-17 | 2001-06-25 | Sanofi-Synthelabo | Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them |
DE20204129U1 (de) | 2002-03-15 | 2002-07-25 | Wella Ag, 64295 Darmstadt | Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen |
WO2005092860A1 (fr) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Composes servant au traitement de maladies |
EP1833480A2 (fr) * | 2004-11-30 | 2007-09-19 | Artesian Therapeutics, Inc. | Composes cardiotoniques dotes d'une activite inhibitrice dirigee contre les recepteurs beta-adrenergiques et la phosphodiesterase |
US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
WO2008094507A2 (fr) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Nouveaux composés de fusion |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
US8722851B2 (en) | 2007-11-02 | 2014-05-13 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A |
EP2488177B1 (fr) | 2008-10-31 | 2016-10-12 | Pain Therapeutics, Inc. | Anti-inflammatoire et analgésique se liant à la filamine a |
CA2779252C (fr) | 2008-10-31 | 2015-05-05 | Pain Therapeutics, Inc. | Analgesique anti-inflammatoire se liant a la filamine a |
US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
CA2741839A1 (fr) * | 2008-11-21 | 2010-05-27 | Pfizer Inc. | 1-oxa-8-azaspiro[4.5]decane-8-carboxamides en tant qu'inhibiteurs de faah |
WO2011137024A1 (fr) * | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase |
US9186354B2 (en) * | 2010-07-23 | 2015-11-17 | Merck Sharp & Dohme Corp. | Pyrrolidine derived β3 adrenergic receptor agonists |
JP2012092038A (ja) | 2010-10-26 | 2012-05-17 | F Hoffmann La Roche Ag | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 |
WO2014011917A2 (fr) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Méthode pour inhiber la phosphorylation de la protéine tau |
EP2872899B1 (fr) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Analyse de la maladie d'alzheimer chez un patient vivant |
GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
JP7357617B2 (ja) * | 2017-12-06 | 2023-10-06 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 心不全およびそれに関連する障害の治療または予防に有用なβ-3アドレナリン受容体のモジュレーター |
-
2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 CA CA3026024A patent/CA3026024A1/fr active Pending
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active IP Right Cessation
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/fr active Search and Examination
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/fr active Active
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active IP Right Grant
- 2017-06-05 MX MX2018015124A patent/MX2018015124A/es unknown
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
-
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-03 PH PH12018502550A patent/PH12018502550A1/en unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
-
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
-
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
-
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
-
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44037A1 (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci | |
MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
MA45985A (fr) | Inhibiteurs de diacylglycérol acyltransférase 2 | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA43131B1 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
MA35460B1 (fr) | Composés et compositions en tant qu'inhibiteurs de kinase c-kit | |
MA44549A1 (fr) | Agents immunorègulateurs | |
MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA50804B1 (fr) | Nouveaux antagonistes des récepteurs de bradykinine b2 | |
MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
MA35459B1 (fr) | Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit | |
MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
MA52948B1 (fr) | Composés | |
MA54386B1 (fr) | Modulateurs de trex1 | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA55821B1 (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression |